FDA delays Staar toric submission
This article was originally published in The Gray Sheet
Executive Summary
Agency asks Staar Surgical to amend its PMA supplement application for the Visian TICL (toric implantable Collamer lens), a refractive phakic implant placed in the posterior chamber of the eye to treat nearsightedness and astigmatism, firm says Nov. 27. In a Nov. 20 letter, FDA requests more information and analysis of clinical data, which Staar says could extend the review period by up to six months. The original application, which included clinical data from a trial of 125 primary eyes with one-year follow up was submitted April 28 as a supplement to Myopic Visian ICL, approved in December 2005 for correction of myopia...
You may also be interested in...
Staar’s Visian TICL requires FDA panel review
PMA supplement for Staar Surgical's Visian TICL toric implantable Collamer lens for treating myopia and astigmatism will require review by the agency's Ophthalmic Devices Panel, contrary to the firm's expectations. As a result, FDA approval will now be "unlikely in 2007, as previously anticipated," Staar says Feb. 6. The panel is needed since Visian TICL is "the first toric phakic implantable lens to be reviewed," according to the company. The supplement, submitted last April, references a December 2005 PMA approval for Staar's Visian ICL for myopia. FDA had asked Staar to amend the Visian TICL supplement last November (1"The Gray Sheet" Dec. 4, 2006, In Brief)...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.